menu
    • menu
    [{"orgOrder":0,"company":"Inoviv","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Inoviv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inoviv \/ Hoxton Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Inoviv \/ Hoxton Ventures"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"HER-096","moa":"CDNF","graph1":"Neurology","graph2":"Phase I","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Herantis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Herantis Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for HER-096

    Menu

    HER-096

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Herantis Pharma

                            Finland arrow
                            Peptide Forum
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            Peptide Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patients Dosed in Final Cohort of HER-096 Parkinson’s Phase 1b Trial

                            Details : HER-096 is a CDNF mimetic that has the potential to protect against the neuronal degeneration and cell death that cause the symptoms of Parkinson’s disease.

                            Product Name : HER-096

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 13, 2025

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inoviv

                            United Kingdom arrow
                            Peptide Forum
                            Not Confirmed

                            Inoviv

                            United Kingdom arrow
                            Peptide Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Hoxton Ventures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Inoviv Secures Investment to Enhance Quantitative Proteomics

                            Details : The net proceeds will be used to accelerate company's drug development pipelines, including HER-096, developed from neurotrophic factor CDNF, a groundbreaking approach to Parkinson's disease.

                            Product Name : HER-096

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Hoxton Ventures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth